MHMatti Hero

Matti Hero

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Matti Hero has a total of 126 co-authors. Here are the top co-authors by number of shared publications:

  • Taneli Raivio

    Stem Cells and Metabolism Research Program (STEMM), Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland

    15 shared publications
  • Leo Dunkel

    William Harvey Research InstituteBarts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK

    11 shared publications
  • Kirsi Vaaralahti

    Department of Physiology, Medicum Unit, and Translational Stem Cell Biology and Metabolism Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland

    8 shared publications
  • Tero Varimo

    Helsinki University Hospital, New Children’s Hospital, Pediatric Research Center, Helsinki University, Helsinki, Finland

    8 shared publications
  • Päivi Johanna Miettinen

    New Children’s Hospital, Pediatric Research Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

    6 shared publications
  • Taneli Raivio

    Helsinki University Hospital, New Children′s Hospital Pediatric Research Center Helsinki Finland

    6 shared publications

Latest Publications

  • Open Access

    Neonatal Anti-seizure Medication Exposure and Long-term Neurological Outcomes

    by Markus Leskinen, Volmar Kaipainen, Mine Öğretir, Marjo Metsäranta, Matti Hero, Samuli Rautava, Miika Koskinen

    Objective: There is limited evidence for Anti-seizure medication (ASM) safety and long-term outcomes in neonates. Phenobarbital is the only ASM accepted by FDA for neonatal use, but it has been linked with adverse effects. Other ASMs are used off-label in neonates. We wanted to examine links between neonatal ASM exposure and later neurological outcomes. Methods: We performed a retrospective observational study of 18,548 infants in intensive care, examining links between ASM exposure and neurological outcomes over follow-up period of median 4.5 years. The clinical data included comprehensive maternal, perinatal, and medication data. Multivariable cause-specific Cox models were used to estimate hazard ratios (HRs) for phenobarbital, levetiracetam, midazolam, and fosphenytoin exposure. Results: Exposure to the median cumulative dose of phenobarbital was associated with increased HR for epilepsy (HR 1.35; 95% CI, 1.11–1.62) visual impairment (HR 1.20; 95% CI, 0.99–1.45), and intellectual disability (HR 1.18; 95% CI, 0.99–1.41). In contrast, levetiracetam was associated with smaller risk increases for cerebral palsy (HR 1.13; 95% CI, 1.03–1.23), epilepsy (HR 1.14; 95% CI 1.05–1.24) and visual impairment (HR 1.18; 95% CI 1.11–1.26). We did not find evidence of a dose-dependent phenobarbital effect, but increased maximum concentrations were associated with elevated hazard ratios for cerebral palsy (HR 1.48; 95% CI, 1.07–2.06) and epilepsy (HR 1.64; 95% CI, 1.14–2.35). Conclusion: The results align with previous findings linking phenobarbital to neurodevelopmental harm and emphasize the need for its cautious use in neonates. Levetiracetam had more favorable safety profile.

  • Open Access

    Puberty‐Promoting Treatment and Psychosocial Well‐Being in Boys With Constitutional Delay of Puberty: A Randomized Controlled Trial

    by Laura Kariola, Tero Varimo, Mitja Lääperi, Hanna Huopio, Sirpa Tenhola, Raimo Voutilainen, Jorma Toppari, Silja Kosola, Päivi J. Miettinen, Olli Raitakari, et al.

    Objective: In boys, constitutional delay of growth and puberty (CDGP) has been associated with diverse negative psychosocial effects. Albeit alleviating distress is one of the main reasons for inducing pubertal development, the impact of puberty‐promoting treatment on psychosocial wellbeing is under‐researched. Our objective was to investigate the impact of puberty‐promoting therapies on the behavioural patterns as defined by the temperament characteristics emotionality, activity, and sociability (EAS) in boys with CDGP. Design: The study is a randomized, controlled, open‐label trial. Patients: Thirty boys were randomized to receive either aromatase inhibitor letrozole (2.5 mg/day) ( n = 15) or intramuscular testosterone (1 mg/kg/every 4 weeks) ( n = 15) for 6 months and followed up to 12 months. To compare our results with healthy peers, an age‐ and postal‐code matched, and a national reference population were collected. Measurements: Temperament characteristics were evaluated with a standardized and validated questionnaire at 0‐, 6‐, and 12‐month visits. Results: In comparison to local peers, boys with CDGP were more withdrawn ( p = 0.02) and experienced less anger ( p = 0.02) and fear ( p = 0.02). Compared to both local and national controls, there was a significant difference in emotionality, CDGP boys being less negatively emotional than peers ( p = 0.04). Sociability was higher in the Lz‐group in comparison to the T‐group both after the 6‐month treatment period (−0.48, 95% CI: 0.89; −0.08, p = 0.019) and at 12‐month follow‐up (−0.72, CI: 95%, −1.12; −0.32, p = 0.001). Conclusion: Overall, boys with CDGP exhibited a generally docile temperament. The administration of puberty‐promoting treatments did not result in any adverse psychosocial effects on the temperament characteristics assessed.


  • Central precocious puberty in boys: secular trend and clinical features

    by Heta Huttunen, Juho Kärkinen, Tero Varimo, Päivi J Miettinen, Taneli Raivio, Matti Hero

    Recent studies suggest that boys enter puberty at a younger age, and the incidence of male central precocious puberty (CPP) is increasing. In this study, we explore the incidence of male CPP and identify key clinical and auxological indicators for organic CPP (OCPP). A retrospective registry-based study. The medical records of 43 boys treated with CPP at the Helsinki University Hospital between 1985 and 2014 were reviewed. Clinical, auxological, and endocrine data of the CPP patients were included in the analyses. Based on brain MRI, 26% of patients had OCPP. Between 2010 and 2014, the CPP incidence in boys was 0.34 per 10 000 (95% CI 0.20-0.60). Between 1990 and 2014, the male CPP incidence increased (incidence rate ratio [IRR] 1.10, P = .001). This increase was driven by rising idiopathic CPP (ICPP) incidence (IRR 1.11, 95% CI 1.05-1.19, P < .001), while OCPP incidence remained stable (P = .41). Compared with the patients with ICPP, the patients with OCPP were younger (P = .006), were shorter (P = .003), and had higher basal serum testosterone levels (P = .038). Combining 2 to 4 of these readily available clinical cues resulted in good to excellent (all, area under the curve 0.84-0.97, P < .001) overall performance, differentiating organic etiology from idiopathic. The estimated incidence of CPP in boys was 0.34 per 10 000, with 26% of cases associated with intracranial pathology. The increase in CPP incidence was driven by rising ICPP rates. Patients with OCPP were characterized by shorter stature, younger age, and higher basal testosterone levels, providing valuable cues for differentiation in addition to brain MRI. Utilizing multiple cues could guide diagnostic decision-making.


  • Open Access

    Health-related quality of life in boys with constitutional delay of growth and puberty

    by Laura Kariola, Tero Varimo, Hanna Huopio, Sirpa Tenhola, Raimo Voutilainen, Silja Kosola, Jorma Toppari, Harri Sintonen, Päivi J. Miettinen, Taneli Raivio, et al.

    Introduction: Constitutional delay of growth and puberty (CDGP) is the most common reason for delayed puberty in healthy male adolescents. The main indication for medical treatment for this condition is psychosocial burden. However, to the best of our knowledge, no previous study has addressed the impact of puberty-promoting treatment on health-related quality of life (HRQoL) among boys with CDGP.Methods: We investigated HRQoL in 22 boys with CDGP, who participated in a randomized controlled trial in four Finnish pediatric endocrinology outpatient clinics between 2013 and 2017. The boys were randomized to receive either aromatase inhibitor letrozole (2.5mg/day; n=11) or intramuscular testosterone (1mg/kg/every 4 weeks; n=11) for 6 months and followed up to 12 months. HRQoL was assessed with a generic self-assessment 16D© instrument developed and validated for adolescents aged 12 to 15 years. The 16D includes 16 dimensions (vitality, sight, breathing, distress, hearing, sleeping, eating, discomfort and symptoms, speech, physical appearance, school and hobbies, mobility, friends, mental function, excretion and depression). The results were compared with an age-matched reference population that included 163 boys from the Finnish capital-city area. The study protocol is registered to ClinicalTrials.gov (registration number: NCT01797718).Results: At baseline, the mean 16D score of the CDGP boys was similar to the age-matched reference population (0.95 vs 0.96, p=0.838). However, the physical appearance score (satisfaction with general appearance, height and weight) was significantly lower in the CDGP boys (0.75 vs 0.92, p=0.004) than their peers. Twelve months after treatment, Appearance had improved significantly (0.75 vs 0.87, p=0.004) and no HRQoL dimension was inferior compared to the age-matched reference population.Discussion: In terms of HRQoL, the main impact of delayed puberty was dissatisfaction with physical appearance. Puberty promoting therapy was associated with a positive change in perceived appearance, with no clear difference between low-dose testosterone and letrozole treatments.


  • Open Access

    The aetiology of extreme tall stature in a screened Finnish paediatric population

    by Juho Kärkinen, Eero Sorakunnas, Päivi J. Miettinen, Taneli Raivio, Matti Hero


  • Serum testosterone and oestradiol predict the growth response during puberty promoting treatment

    by Heta Huttunen, Tero Varimo, Hanna Huopio, Raimo Voutilainen, Sirpa Tenhola, Päivi J. Miettinen, Taneli Raivio, Matti Hero

    Objective: The influence of androgens and oestrogens on growth is complex, and understanding their relative roles is important for optimising the treatment of children with various disorders of growth and puberty.Design: We examined the proportional roles of androgens and oestrogens in the regulation of pubertal growth in boys with constitutional delay of growth and puberty (CDGP). The study compared 6‐month low‐dose intramuscular testosterone treatment (1 mg/kg/month; n = 14) with per oral letrozole treatment (2.5 mg/day; n = 14) which inhibits conversion of androgens to oestrogen.Patients: Boys with CDGP were recruited to a randomized, controlled, open‐label trial between 2013 and 2017 (NCT01797718).Measurements: The patients were evaluated at 0‐, 3‐ and 6‐month visits, and morning blood samples were drawn. Linear regression models were used for data analyses.Results: In the testosterone group (T‐group), serum testosterone concentration correlated with serum oestradiol concentration at the beginning of the study and at 3 months, whereas in the letrozole group (Lz‐group) these sex steroids correlated only at baseline. Association between serum testosterone level and growth velocity differed between the T and Lz groups, as each nmol/L increase in serum testosterone increased growth velocity 2.7 times more in the former group. Serum testosterone was the best predictor of growth velocity in both treatment groups. In the Lz‐group, adding serum oestradiol to the model significantly improved the growth estimate. Only the boys with serum oestradiol above 10 pmol/L had a growth velocity above 8 cm/year.Conclusions: During puberty promoting treatment with testosterone or aromatase inhibitor letrozole, growth response is tightly correlated with serum testosterone level. A threshold level of oestrogen appears to be needed for an optimal growth rate that corresponds to normal male peak height velocity of puberty. Serum testosterone 1 week after the injection and serum testosterone and oestradiol 3 months after the onset of aromatase inhibitor treatment can be used as biomarkers for treatment response in terms of growth.


  • Etiology of severe short stature below −3 SDS in a screened Finnish population

    by Juho Kärkinen, Päivi J Miettinen, Taneli Raivio, Matti Hero

    Objective:: To describe the etiology of severe short stature in the Helsinki University Hospital district covering a population of 1.2 million that is subject to frequent growth monitoring and screening rules during childhood. Design:: Retrospective cohort study. Methods:: We identified all subjects born 1990 or later with a height SD score <−3, after the age of 3 years, from the Helsinki University Hospital district growth database. A total of 785 subjects (376 females and 409 males) fulfilled our inclusion criteria; we reviewed their medical records and growth data and report their underlying diagnoses. Results:: A pathological cause for short stature was diagnosed in 76% of the girls and 71% of the boys (P = NS). Syndromes were the most numerous pathological cause (n = 160; 20%), followed by organ disorders (n = 127; 16%), growth hormone deficiency (GHD, n = 94; 12%), SGA without catch-up growth (n = 73; 9%), and skeletal dysplasias (n = 57; 7%). Idiopathic short stature (ISS) was diagnosed in 210 (27%) subjects. The probability of growth-related pathology, particularly of a syndrome or skeletal dysplasia, increased with the shorter height SD score and the greater deviation from the target height. Sitting height to height SDS was increased in subjects with ISS, GHD, and SGA (all P < 0.01). Conclusions:: Height <−3 SDS after 3 years of age usually results from a pathological cause and should be thoroughly investigated in specialized health care. The chance of finding a specific etiology increased with the severity of short stature, and the mismatch with target height.


  • Pituitary and Neuroendocrinology

    by Matti Hero, Yafei Wang, Päivi J Miettinen, Taneli Raivio

  • Open Access

    Loss-of-Function Variants in TBC1D32 Underlie Syndromic Hypopituitarism

    by Johanna Hietamäki, Louise C Gregory, Sandy Ayoub, Anna-Pauliina Iivonen, Kirsi Vaaralahti, Xiaonan Liu, Nina Brandstack, Andrew J Buckton, Tiina Laine, Johanna Känsäkoski, et al.

    Context Congenital pituitary hormone deficiencies with syndromic phenotypes and/or familial occurrence suggest genetic hypopituitarism; however, in many such patients the underlying molecular basis of the disease remains unknown. Objective To describe patients with syndromic hypopituitarism due to biallelic loss-of-function variants in TBC1D32, a gene implicated in Sonic Hedgehog (Shh) signaling. Setting Referral center. Patients A Finnish family of 2 siblings with panhypopituitarism, absent anterior pituitary, and mild craniofacial dysmorphism, and a Pakistani family with a proband with growth hormone deficiency, anterior pituitary hypoplasia, and developmental delay. Interventions The patients were investigated by whole genome sequencing. Expression profiling of TBC1D32 in human fetal brain was performed through in situ hybridization. Stable and dynamic protein-protein interaction partners of TBC1D32 were investigated in HEK cells followed by mass spectrometry analyses. Main Outcome Measures Genetic and phenotypic features of patients with biallelic loss-of-function mutations in TBC1D32. Results The Finnish patients harboured compound heterozygous loss-of-function variants (c.1165_1166dup p.(Gln390Phefs*32) and c.2151del p.(Lys717Asnfs*29)) in TBC1D32; the Pakistani proband carried a known pathogenic homozygous TBC1D32 splice-site variant c.1372 + 1G > A p.(Arg411_Gly458del), as did a fetus with a cleft lip and partial intestinal malrotation from a terminated pregnancy within the same pedigree. TBC1D32 was expressed in the developing hypothalamus, Rathke’s pouch, and areas of the hindbrain. TBC1D32 interacted with proteins implicated in cilium assembly, Shh signaling, and brain development. Conclusions Biallelic TBC1D32 variants underlie syndromic hypopituitarism, and the underlying mechanism may be via disrupted Shh signaling.


  • Open Access

    Letrozole Monotherapy in Pre- and Early-Pubertal Boys Does Not Increase Adult Height

    by Tero Varimo, Sanna Toiviainen-Salo, Taneli Raivio, Liisa Kerttula, Leo Dunkel, Matti Hero

    Background: Aromatase inhibitors (AIs) have been used in boys with idiopathic short stature (ISS) to promote growth despite the lack of actual data regarding treatment effect on adult height. In this study, we characterized adult heights and long-term follow-up in AI-treated boys with ISS. Methods: Adult heights and long-term follow-up data, including spine MRIs, of a randomized, double-blind, placebo-controlled trial of boys who were treated with letrozole (Lz) (2.5 mg/d) or placebo (Pl) for 2 years during prepuberty and early puberty. The mean bone ages at treatment cessation were 10.2 and 10.8 years, respectively. Results: Adult heights were similar between the boys treated with Lz (n = 10) and those who received Pl (n = 10) (164.8 ± 4.0 vs. 163.7 ± 3.7 cm, p = 0.49, respectively). In either group, the adult heights did not differ from predicted adult heights at start of the study [Pl: 163.7 (3.7) cm vs. 166.9 (3.3), p = 0.06; Lz: 164.8 (4.0) cm vs. 167.6 (7.9), p = 0.20, respectively]. Long-term follow-up data showed that the frequency of subjects with a vertebral deformity was similar between the groups (Lz, 29% and Pl, 22%, p = 0.20), and no single comorbidity was clearly enriched in either group. Conclusions: The Lz-treated boys had similar adult heights with the subjects who received Pl for 2 years, which indicates that the treatment is not beneficial when given to pre- or early-pubertal boys. Previously observed vertebral deformities ameliorated during follow-up, which supports the skeletal safety of Lz therapy in children and adolescents.